Immunotherapy shows promise for rare chest cancers

NCT ID NCT03134118

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This study tests the drug nivolumab in 55 people with advanced thymoma or thymic carcinoma that has worsened after initial chemotherapy. The goal is to see if nivolumab can slow cancer growth and how safe it is. Participants receive nivolumab infusions, and researchers track tumor response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Academisch Ziekenhuis Maastricht

    Maastricht, 6202, Netherlands

  • Assistance Publique - Hopitaux de Marseille - Hopital Nord (APHM)

    Marseille, France

  • CHU Toulouse - Hopital Larrey

    Toulouse, 31059, France

  • CHU de Brest

    Brest, 29200, France

  • CHU de Grenoble - La Tronche - Hôpital A. Michallon

    La Tronche, 38700, France

  • CHU de Lyon - Hopital Louis Pradel

    Bron, 69500, France

  • Centre Francois Baclesse

    Caen, 14076, France

  • Erasmus MC

    Rotterdam, Netherlands

  • Gustave Roussy

    Villejuif, 94805, France

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Institut Curie- Hopital de Paris

    Paris, 75248, France

  • Institut Jules Bordet

    Brussels, Belgium

  • NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital

    Glasgow, United Kingdom

  • Royal Marsden Hospital - Chelsea, London

    London, United Kingdom

  • Royal Marsden Hospital - Sutton, Surrey

    Sutton, United Kingdom

  • The Christie NHS Foundation Trust

    Wythenshawe, M23 9LT, United Kingdom

  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    Amsterdam, 1066, Netherlands

  • UniversitaetsSpital Zurich

    Zurich, Switzerland

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Belgium

  • Vall d'Hebron Institut d'Oncologia

    Barcelona, Spain

Conditions

Explore the condition pages connected to this study.